目的 探究喘可治注射液聯(lián)合沙美特羅替卡松治療支氣管哮喘慢性持續(xù)期的臨床療效。方法 選取2012年1月-2015年12月在四川省人民醫(yī)院接受治療的支氣管哮喘持續(xù)期患者96例，隨機分為對照組和治療組，每組各48例。對照組患者接受沙美特羅替卡松粉吸入劑治療，1吸/次，2次/d。治療組患者在對照組的治療基礎上肌肉注射喘可治注射液，4 mL/次，2次/d。兩組均連續(xù)治療40 d。觀察兩組的臨床療效，同時比較兩組患者治療前后肺功能指標和ACT積分的變化情況。結果 治療后，對照組和治療組的總有效率分別為89.58%、100.00%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者的肺活量、用力肺活量、第一秒用力肺活量均較治療前顯著提高，同組治療前后差異有統(tǒng)計學意義（P<0.05）；治療后，治療組肺活量、用力肺活量、第一秒用力肺活量高于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組ACT積分高于同組治療前，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；治療后，治療組ACT積分高于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。結論 喘可治注射液聯(lián)合沙美特羅替卡松具有較好的臨床療效，可明顯改善患者的肺功能，緩解支氣管哮喘慢性持續(xù)期的癥狀，具有一定的臨床推廣應用價值。

Objective To explore the effect of Chuankezhi Injection combined with salmeterol in treatment of chronic duration of bronchial asthma. Methods Patients (96 cases) with bronchial asthma in chronic duration in Sichuan Provincial People's Hospital from January 2012 to December 2015 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were received Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation, 1absorption/time, twice daily. Patients in the treatment group were im administered with Chuankezhi Injection on the basis of the control group, 4 mL/time, twice daily. Patients in two groups were treated for 40 d. After treatment, the efficacy was evaluated, and the changes of indicators of pulmonary function and ACT integral in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 89.58% and 100.00%, respectively, and there were differences between two groups (P<0.05). After treatment, vital capacity, forced vital capacity, and forced vital capacity in the first second in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, vital capacity, forced vital capacity, and forced vital capacity in the first seconds in the treatment group were higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, ACT integrals in two group were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, ACT integral in the treatment group was higher than that in the control group, with significant difference between two groups (P<0.05). Conclusion Chuankezhi Injection combined with salmeterol has clinical curative effect in treatment of chronic duration of bronchial asthma, and can obviously improve the lung function, and alleviate the symptoms of bronchial asthma chronic duration, which has a certain clinical application value.